Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Four things you should know to be #HepAware.
Gilead Sciences CEO defends high drug prices and claims the CDC does not own the patent to HIV prevention pill Truvada.
Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.
If Black women had white women’s lower HIV rate, 93% of their annual new infections would be averted.
Do not fall for Gilead’s vile marketing ploy.
This will provide free PrEP to as many as 200,000 uninsured Americans until 2030.
Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.
That means more money for the CDC and HIV programs. But the future of these funding bills remains unclear.
At press time, more than 700 cases of the highly contagious disease were confirmed in 22 states so far.
Transgender women—notably, those who are Black and Latina—experience disproportionately high rates of HIV.
About 60 percent of young people living with HIV don’t know their status.
As messy and challenging as community can be, we are the only road to ending the epidemic.
While other HIV conferences have felt complacent, AIDSWatch still centers activism. This year we spoke back to the CDC Director.
The day after CDC Director Robert Redfield was confronted at AIDSWatch, hill visits by advocates produced “strong interest” in hearings.
The high cost of antiretrovirals may get passed along to consumers through co-pays, co-insurance or deductibles.
The new federal plan to combat HIV has the audacious goal of cutting the annual infection rate by 90 percent by 2030.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.